<![CDATA[Genmab — August 2012]]>Ofatumumab i nyt fase 3 http://clinicaltrials.gov/ct2/show/NCT01659021?term=ofatumumab&rank=44

]]>https://dev.proinvestor.com/forum/topic/451449/genmab-august-2012RSS for NodeFri, 19 Jun 2026 11:34:18 GMTWed, 08 Aug 2012 08:50:57 GMT60<![CDATA[Reply to Genmab — August 2012 on Fri, 31 Aug 2012 11:22:38 GMT]]>

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/10068102https://dev.proinvestor.com/forum/post/10068102Fri, 31 Aug 2012 11:22:38 GMT<![CDATA[Reply to Genmab — August 2012 on Wed, 29 Aug 2012 09:55:16 GMT]]>Ja det skal nok komme til at give lidt i kassen på sigt, altså gode kombinationsbehandlinger 🙂

]]>https://dev.proinvestor.com/forum/post/10068101https://dev.proinvestor.com/forum/post/10068101Wed, 29 Aug 2012 09:55:16 GMT<![CDATA[Reply to Genmab — August 2012 on Wed, 29 Aug 2012 08:42:30 GMT]]>
ERROR: The request could not be satisfied

favicon

(www.asco.org)

]]>https://dev.proinvestor.com/forum/post/10068104https://dev.proinvestor.com/forum/post/10068104Wed, 29 Aug 2012 08:42:30 GMT<![CDATA[Reply to Genmab — August 2012 on Wed, 29 Aug 2012 07:58:38 GMT]]>For lige at minde om noget andet gammelt nyt...

]]>https://dev.proinvestor.com/forum/post/10068103https://dev.proinvestor.com/forum/post/10068103Wed, 29 Aug 2012 07:58:38 GMT<![CDATA[Reply to Genmab — August 2012 on Wed, 29 Aug 2012 07:58:15 GMT]]>Ibrutinib: PCI-32765 combined with ofatumumab is well tolerated and highly active (100% ORR) in pts with heavily pre-treated R/R CLL/SLL.

]]>https://dev.proinvestor.com/forum/post/10068100https://dev.proinvestor.com/forum/post/10068100Wed, 29 Aug 2012 07:58:15 GMT<![CDATA[Reply to Genmab — August 2012 on Wed, 29 Aug 2012 05:40:36 GMT]]>Ja det er skønt, det booster omsætningen indtil Arzerra rulles ud i 1.line CLL 🐵

]]>https://dev.proinvestor.com/forum/post/10068097https://dev.proinvestor.com/forum/post/10068097Wed, 29 Aug 2012 05:40:36 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 12:31:26 GMT]]>det er ret vildt, med alle de patienter

]]>https://dev.proinvestor.com/forum/post/10068099https://dev.proinvestor.com/forum/post/10068099Tue, 28 Aug 2012 12:31:26 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:36:25 GMT]]>tak til jer begge for info

]]>https://dev.proinvestor.com/forum/post/10068095https://dev.proinvestor.com/forum/post/10068095Tue, 28 Aug 2012 10:36:25 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:14:13 GMT]]>De tre nye OFA fase 3 med Ibrutinib, dinaciclib og GS 1101 er alle rekrutterende nu. I alt cirka 800 Ofa patienter

]]>https://dev.proinvestor.com/forum/post/10068093https://dev.proinvestor.com/forum/post/10068093Tue, 28 Aug 2012 10:14:13 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:11:40 GMT]]>Ja og i princippet en række andre videoer er da spændende at høre !

]]>https://dev.proinvestor.com/forum/post/10068105https://dev.proinvestor.com/forum/post/10068105Tue, 28 Aug 2012 10:11:40 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:00:27 GMT]]>

]]>https://dev.proinvestor.com/forum/post/10068092https://dev.proinvestor.com/forum/post/10068092Tue, 28 Aug 2012 10:00:27 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:00:11 GMT]]>

]]>https://dev.proinvestor.com/forum/post/10068090https://dev.proinvestor.com/forum/post/10068090Tue, 28 Aug 2012 10:00:11 GMT<![CDATA[Reply to Genmab — August 2012 on Tue, 28 Aug 2012 10:00:08 GMT]]>Ligeledes denne video - ofatumumab + ibrutinib, altså den kombinationsbehandling Jan også har talt om

]]>https://dev.proinvestor.com/forum/post/10068096https://dev.proinvestor.com/forum/post/10068096Tue, 28 Aug 2012 10:00:08 GMT<![CDATA[Reply to Genmab — August 2012 on Mon, 27 Aug 2012 10:56:06 GMT]]>paradigm shifting I like!

]]>https://dev.proinvestor.com/forum/post/10068089https://dev.proinvestor.com/forum/post/10068089Mon, 27 Aug 2012 10:56:06 GMT<![CDATA[Reply to Genmab — August 2012 on Mon, 27 Aug 2012 10:53:27 GMT]]>http://www.proinvestor.com/boards/60312/

]]>https://dev.proinvestor.com/forum/post/10068088https://dev.proinvestor.com/forum/post/10068088Mon, 27 Aug 2012 10:53:27 GMT<![CDATA[Reply to Genmab — August 2012 on Mon, 27 Aug 2012 09:47:38 GMT]]>Gammel, men alligevel: http://www.youtube.com/watch?v=dKZ-4y_uAqk

]]>https://dev.proinvestor.com/forum/post/10068091https://dev.proinvestor.com/forum/post/10068091Mon, 27 Aug 2012 09:47:38 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 17:13:28 GMT]]>Beklager lige Tofacitinip - det er jo et Pfizer stof og ikke fra GSK

]]>https://dev.proinvestor.com/forum/post/10068094https://dev.proinvestor.com/forum/post/10068094Sat, 25 Aug 2012 17:13:28 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 11:31:59 GMT]]>da også spændende at Genmab vil komme en ny IND kandidat i 2012. Den glæder jeg mig til at høre noget om. 🙂 En ny Dara måske 😄

]]>https://dev.proinvestor.com/forum/post/10068087https://dev.proinvestor.com/forum/post/10068087Sat, 25 Aug 2012 11:31:59 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 08:12:29 GMT]]>Jeg hørte godt Winkels udtalelse - men soon kan være lang tid i biotech verdenen 🙂 Men JAK inhibitoren kan godt være svaret på at Arzerra ikke er på vej i RA

]]>https://dev.proinvestor.com/forum/post/10068098https://dev.proinvestor.com/forum/post/10068098Sat, 25 Aug 2012 08:12:29 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 07:33:19 GMT]]>GSK er formentlig også tæt på at få godkendt deres JAK inhibitor Tofacitinib i RA, så det er helt sikkert en indikation de satser meget p, men desværre nok ikke med Arzerra !

]]>https://dev.proinvestor.com/forum/post/10068085https://dev.proinvestor.com/forum/post/10068085Sat, 25 Aug 2012 07:33:19 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 07:33:04 GMT]]>Jan sagde på Q&A senest, at GSk i løbet af kort tid ville udtale sig om planerne i de autoimmune sygdomme !

]]>https://dev.proinvestor.com/forum/post/10068084https://dev.proinvestor.com/forum/post/10068084Sat, 25 Aug 2012 07:33:04 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 07:20:12 GMT]]>Tror GSK alene går efter MS pt - men det er også et enormt marked. Hvornår GSK melder noget ud om det er uvist, men Genmab udtaler sig ikke jf det seneste vi har hørt fra Winkel

]]>https://dev.proinvestor.com/forum/post/10068081https://dev.proinvestor.com/forum/post/10068081Sat, 25 Aug 2012 07:20:12 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 05:34:32 GMT]]>Ritux er 3.linje behandling i RA efter methotrexat+steroid og TNF-a. Konkurrencen med ritux og evt biosimilars synes op ad bakke i en ikke-malign
indikation 3.linje-behandling

]]>https://dev.proinvestor.com/forum/post/10068086https://dev.proinvestor.com/forum/post/10068086Sat, 25 Aug 2012 05:34:32 GMT<![CDATA[Reply to Genmab — August 2012 on Sat, 25 Aug 2012 05:32:08 GMT]]>GSK skrev i 2010 at de ville evaluere Arzerra s.c. i RA indikationen. De er ikke gået videre med det i de 2år og nu tyder det ikke ligefrem på at de satser på Arzerra i RA

]]>https://dev.proinvestor.com/forum/post/10068079https://dev.proinvestor.com/forum/post/10068079Sat, 25 Aug 2012 05:32:08 GMT